Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer
Pasi A. Jänne, Ian C. P. Smith(AstraZeneca (United Kingdom)), Gael McWalter(AstraZeneca (United Kingdom)), Helen Mann(AstraZeneca (United Kingdom)), Brian Dougherty(AstraZeneca (United Kingdom)), Jill Walker(AstraZeneca (United Kingdom)), Maria Orr(AstraZeneca (United Kingdom)), Darren Hodgson(AstraZeneca (United Kingdom)), Alice T. Shaw, José Rodrigues Pereira, G. Jeannin, Johan Vansteenkiste, C.H. Barrios, Fábio Franke, Lucio Crinò, Paul D. Smith(AstraZeneca (United Kingdom))
Cited by 75Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis